Psychiatric Digital Biomarkers Market Size, Share, Trends, Industry Analysis Report: By Type (Wearable, Mobile-Based Applications, Sensors, and Others), Clinical Practice, End Use, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) – Market Forecast, 2025–2034
- Published Date:Mar-2025
- Pages: 129
- Format: PDF
- Report ID: PM5446
- Base Year: 2024
- Historical Data: 2020-2023
Psychiatric Digital Biomarkers Market Overview
The psychiatric digital biomarkers market size was valued at USD 630.40 million in 2024 and is expected to reach USD 782.65 million by 2025 and USD 5,543.77 million by 2034, exhibiting a CAGR of 24.3% during 2025–2034.
The psychiatric digital biomarkers market refers to the industry focused on developing and utilizing digital tools, such as wearables, smartphone applications, and AI-driven analytics, to objectively measure behavioral, cognitive, and physiological markers associated with mental health conditions. These biomarkers enable early detection, monitoring, and personalized treatment of psychiatric disorders such as depression, schizophrenia, and bipolar disorder, enhancing clinical decision-making and pharmaceutical research.
The integration of artificial intelligence (AI) and machine learning (ML) enhances the accuracy and predictive capabilities of psychiatric digital biomarkers. It enables early diagnosis and personalized treatment approaches, which significantly contributes to the psychiatric digital biomarkers market growth. Moreover, the growing adoption of telehealth solutions is boosting the need for digital biomarkers to provide continuous, real-time mental health assessments outside traditional clinical settings, which is fueling the market expansion.
To Understand More About this Research: Request a Free Sample Report
Pharmaceutical companies are increasingly leveraging psychiatric digital biomarkers for drug development, patient stratification, and clinical trial optimization, contributing to psychiatric digital biomarkers market expansion. Furthermore, growing regulatory focus on digital health tools, including initiatives from the FDA and EMA, is encouraging innovation and accelerating approvals for digital biomarkers in psychiatric applications, which is driving market dynamics.
Psychiatric Digital Biomarkers Market Dynamics
Rising Prevalence of Mental Health Disorders
The rising prevalence of mental health disorders, including depression, anxiety, and schizophrenia, is significantly contributing to the psychiatric digital biomarkers market growth. According to Mental Health America, between 2021 and 2022, nearly 60 million adults in the US (i.e., 23% of the population) experienced a mental illness. As the global burden of psychiatric conditions escalates, there is increasing market demand for objective, data-driven diagnostic and monitoring tools to enhance early detection and treatment efficacy. Traditional psychiatric assessments often rely on subjective evaluation, creating a strong need for digital biomarkers that provide quantifiable insights. This shift is driving market expansion by attracting investments in innovative technologies that leverage AI, wearables, and mobile applications. The increasing focus on precision psychiatry and personalized medicine biomarkers is enhancing the market value, positioning digital biomarkers as a critical component in the future of mental healthcare.
Advancements in Wearable and Mobile Health Technology
Advancements in wearable and mobile health technology are significantly contributing to the psychiatric digital biomarkers market demand by improving accessibility, usability, and real-time monitoring capabilities. The widespread adoption of smartwatches, biosensors, and mobile applications equipped with mental health tracking functionalities is driving demand for noninvasive, continuous psychiatric assessment tools. These technologies enable real-time data collection on physiological and behavioral parameters, enhancing diagnostic accuracy and treatment personalization. Additionally, AI-driven analytics integrated with wearables provide actionable insights for clinicians, supporting early intervention and remote patient management. Apollo Neuro launched the first AI-driven responsive wearable designed to enhance sleep, reduce stress, and improve overall mental and physical health. Rising digital health adoption is attracting investments and boosting the development of next-generation psychiatric digital biomarker solutions.
Psychiatric Digital Biomarkers Market Segment Insights
Psychiatric Digital Biomarkers Market Assessment by Type Outlook
The global psychiatric digital biomarkers market segmentation, based on type, includes wearable, mobile-based applications, sensors, and others. In 2024, the wearable segment accounted for the largest market share due to the growing integration of advanced biosensors in smartwatches, fitness trackers, and wearable EEG devices for continuous mental health monitoring. These devices enable real-time tracking of physiological and behavioral biomarkers such as heart rate variability, sleep patterns, and stress levels. The demand for remote psychiatric assessments, combined with AI-driven analytics, is further accelerating adoption among clinicians and researchers. Additionally, increasing regulatory approvals and clinical validation of wearables for psychiatric applications are enhancing market value, positioning wearable technology as a key driver of psychiatric digital biomarkers market development.
Psychiatric Digital Biomarkers Market Evaluation by End Use Outlook
The global psychiatric digital biomarkers market segmentation, based on end use, includes healthcare companies, healthcare providers, payers, and others. In 2024, the healthcare companies segment accounted for the largest market share due to the increasing adoption of psychiatric digital biomarkers for early diagnosis, treatment personalization, and patient monitoring. Leading pharmaceutical and MedTech firms are investing in AI-powered biomarker analytics to support drug development and clinical trials, strengthening market demand. Additionally, healthcare providers are integrating digital biomarkers into telepsychiatry services, improving remote mental healthcare delivery. Strategic collaborations between healthcare companies and digital health startups are propelling market expansion, and raising awareness about objective psychiatric assessments is solidifying the dominance of healthcare firms in this sector.
Psychiatric Digital Biomarkers Market Regional Analysis
By region, the study provides psychiatric digital biomarkers market insights into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2024, North America accounted for the largest share of the psychiatric digital biomarkers market revenue due to the region’s advanced healthcare infrastructure, strong investments in digital health technologies, and increasing adoption of AI-driven mental health diagnostics. The presence of key industry players launching new products, coupled with favorable regulatory policies supporting digital biomarkers in clinical applications, has accelerated market expansion. In June 2024, Feel Therapeutics launched the Feel Monitor, an advanced AI-powered wearable designed for mental health monitoring. Developed in compliance with the FDA’s QMSR for medical devices, it sets a new standard in precision-driven mental health assessment. Additionally, the rising prevalence of mental health disorders, along with growing reimbursement support for digital mental health solutions, has driven market demand. Collaboration between research institutions and tech companies in the US and Canada has further strengthened innovation, contributing to the overall regional market growth.
The Europe psychiatric digital biomarkers market is expected to register the highest CAGR during the forecast period due to the region's increasing focus on digital health transformation, government initiatives supporting mental health research, and rising adoption of wearable and AI-powered diagnostic tools. For instance, the EU4Health program funded a USD 11.52 million project that aligns with the European Commission's comprehensive mental health strategy and supports the WHO's mental health action framework from 2021 to 2025. The growing integration of digital biomarkers in psychiatric clinical trials and healthcare systems is fueling market expansion. Additionally, advancements in neurotechnology and increased collaboration between healthcare providers, MedTech firms, and academic institutions are contributing to the region’s market dynamics. The demand for remote psychiatric monitoring solutions, driven by an aging population and increasing awareness, is further accelerating market growth.
Psychiatric Digital Biomarkers Market – Key Players & Competitive Analysis Report
The competitive landscape of the psychiatric digital biomarkers market is characterized by the presence of established healthcare technology firms, digital health startups, and pharmaceutical companies investing in AI-driven mental health solutions. Key players are focusing on advancing machine learning algorithms, wearable biosensors, and mobile-based psychiatric assessments to enhance diagnostic accuracy and real-time monitoring. Strategic collaborations between technology firms and healthcare providers are driving innovation, while regulatory approvals and data security compliance remain critical differentiators. Companies are also expanding their product portfolios through acquisitions, R&D investments, and partnerships with academic institutions. The increasing adoption of digital biomarkers in clinical trials has further intensified competition, with firms competing to integrate these solutions into personalized psychiatric care models.
Biogen is engaged in the discovery, development, and delivery of innovative therapies for serious neurological diseases. Specializing in neuroscience, Biogen was founded in 1978 and is headquartered in Massachusetts, USA. The company's product portfolio includes treatments for multiple sclerosis, spinal muscular atrophy, and Alzheimer's disease. Biogen provides comprehensive solutions for neurological conditions, focusing on advancing digital biomarkers and personalized medicine. The company has a significant presence globally, with operations in multiple countries. Biogen has been involved in developing digital biomarkers for neurodegenerative diseases, which is crucial for early diagnosis and personalized treatment.
Empatica Inc. is engaged in the development of wearable devices and software for monitoring human health. The company was founded in 2011, and headquartered in Massachusetts, USA. It specializes in creating wearable sensors that track physiological signals, providing insights into neurological conditions. Empatica's product portfolio includes the Embrace smartwatch, designed to detect seizures and provide alerts. The company offers services related to data analytics and health monitoring, with a presence in North America and Europe.
List of Key Companies in Psychiatric Digital Biomarkers Market
- Biogen
- Brainomix
- Clario
- Empatica Inc.
- Huma
- IXICO plc
- Koneksa Health
- PureTech Health PLC
- Sonde Health, Inc.
- VivoSense
Psychiatric Digital Biomarkers Industry Developments
In March 2024, Indivi partnered with Biogen to advance digital health technology and digital biomarkers for Parkinson’s disease
In July 2023, Quanterix launched the LucentAD biomarker blood test to aid physicians in diagnosing Alzheimer's disease in patients. The test, which measures p-Tau 181, was designed to assist in evaluating patients showing early cognitive symptoms consistent with Alzheimer's disease, providing a simplified assessment process for clinicians to determine amyloid pathology.
Psychiatric Digital Biomarkers Market Segmentation
By Type Outlook (Revenue – USD Million, 2020–2034)
- Wearable
- Mobile-Based Applications
- Sensors
- Others
By Clinical Practice Outlook (Revenue – USD Million, 2020–2034)
- Diagnostic Psychiatric Digital Biomarkers
- Monitoring Psychiatric Digital Biomarkers
- Predictive and Prognostic Psychiatric Digital Biomarkers
- Others
By End Use Outlook (Revenue – USD Million, 2020–2034)
- Healthcare Companies
- Healthcare Providers
- Payers
- Others
By Regional Outlook (Revenue – USD Million, 2020–2034)
- North America
- US
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Netherlands
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Malaysia
- South Korea
- Indonesia
- Australia
- Vietnam
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Mexico
- Brazil
- Argentina
- Rest of Latin America
Psychiatric Digital Biomarkers Market Report Scope
|
Report Attributes |
Details |
|
Market Size Value in 2024 |
USD 630.40 Million |
|
Market Size Value in 2025 |
USD 782.65 Million |
|
Revenue Forecast by 2034 |
USD 5,543.77 Million |
|
CAGR |
24.3% from 2025 to 2034 |
|
Base Year |
2024 |
|
Historical Data |
2020–2023 |
|
Forecast Period |
2025–2034 |
|
Quantitative Units |
Revenue in USD Million, and CAGR from 2025 to 2034 |
|
Report Coverage |
Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
|
Segments Covered |
|
|
Regional Scope |
|
|
Competitive Landscape |
|
|
Report Format |
|
|
Customization |
Report customization as per your requirements with respect to countries, regions, and segmentation. |
FAQ's
The market size was valued at USD 630.40 million in 2024 and is projected to grow to USD 5,543.77 million by 2034.
The global market is projected to register a CAGR of 24.3% during the forecast period.
In 2024, North America accounted for the largest share of the psychiatric digital biomarkers market due to the region’s advanced healthcare infrastructure, strong investments in digital health technologies, and increasing adoption of AI-driven mental health diagnostics.
A few of the key players in the market are Biogen; Brainomix; Clario; Empatica Inc.; Huma; IXICO plc; Koneksa Health; PureTech Health PLC; Sonde Health, Inc.; and VivoSense.
In 2024, the wearable segment accounted for the largest market share due to the growing integration of advanced biosensors in smartwatches, fitness trackers, and wearable EEG devices for continuous mental health monitoring.
In 2024, the healthcare companies segment accounted for the largest market share due to the increasing adoption of psychiatric digital biomarkers for early diagnosis, treatment personalization, and patient monitoring.
© 2025 Polaris Market Research and Consulting. All rights reserved
